Trial Profile
A Randomized, Double-Blind, Active-Controlled Phase 3 Study Evaluating the Efficacy and Safety of ABP 959 Compared With Eculizumab in Adult Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 Feb 2024
Price :
$35
*
At a glance
- Drugs Eculizumab (Primary)
- Indications Paroxysmal nocturnal haemoglobinuria
- Focus Registrational; Therapeutic Use
- Acronyms DAHLIA
- Sponsors Amgen
- 12 Dec 2023 Results(n=42) presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 15 Jun 2023 Results assessing sensitivity and subgroup analyses presented at the 28th Congress of the European Haematology Association.
- 13 Dec 2022 Results assessing the efficacy and safety of ABP 959 as compared with eculizumab reference product in paroxysmal nocturnal hemoglobinuria, presented at the 64th American Society of Hematology Annual Meeting and Exposition.